GET DAILY SIGNALSUnitedHealth (UNH) Stock: Analyst Targets Signal +22% Upside to $480
Key Takeaways
- The central UNH stock price target examined here is $480, roughly 22% above the latest verified price near $394.
- This target is the arithmetic mean of roughly a dozen recent, individually verifiable analyst price targets, rounded to a clean level (about $477 before rounding); the broader S&P Global-polled average of 26 analysts is $476.64.
- Analyst targets span a wide range from about $380 to $531, reflecting genuine disagreement over the pace of UnitedHealth's earnings recovery.
- The strongest supports are a third-quarter 2026 earnings beat, raised full-year guidance, and expected Medicare Advantage margin recovery.
- The biggest risks are regulatory and policy uncertainty, a U.S. Department of Justice probe, and commercial medical-cost pressure.
- Readers can track the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper context.
- Explore Trending AI Robots to see how AI-driven trading tools are scanning the market in real time.
Analyst Price Targets and Consensus View
UnitedHealth Group Incorporated (UNH) is a stock, not an ETF, and it carries unusually wide analyst coverage. The central target of $480 is the arithmetic mean of recent, individually attributed price targets, rounded from roughly $477, rather than any single firm's figure or a headline consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent targets include Morgan Stanley at $531, JPMorgan at $524, RBC Capital at $498, Mizuho at $500, Bernstein at $500, Goldman Sachs at $490, Wells Fargo at $487, Evercore ISI at $480, Argus at $470, Raymond James at $450, Barclays at $440, Baird at $427, and TD Cowen at $402. For context, S&P Global's poll of 26 analysts shows an average of $476.64, with a low near $380 and a high of $531, closely matching this calculation.
Views differ sharply. More bullish firms emphasize a faster-than-expected Medicare Advantage and Optum Health recovery; more cautious names, including TD Cowen's Hold and Baird's Neutral, argue that near-term valuation already prices in much of the anticipated 2027–2028 earnings rebound. That wide $380-to-$531 spread is the key signal: the mean is useful, but it is not a guarantee.
Current Market Position and Path Toward the Target
UNH last closed near $394.15, giving it a market capitalization of roughly $353 billion and a 52-week range of about $255.97 to $461.62. Reaching $480 from $394 requires an advance of approximately 22%, a substantial move that would also carry the shares above their 52-week high.
The path would likely depend on sustained EPS (earnings per share) growth. The company beat third-quarter 2026 expectations and raised its full-year adjusted EPS guidance to at least $20.50, while management signaled that the 2027 consensus of roughly $22.63 may be conservative. At a forward P/E (price-to-earnings ratio) near 17, any re-rating toward a higher multiple, combined with earnings growth, is what would have to drive the move.
What Could Support a Move Toward the Target
- Earnings momentum: Q3 2026 EPS rose sharply year over year, and full-year guidance was raised, reinforcing the turnaround narrative.
- Medicare Advantage recovery: Analysts expect sector-wide margin repair from repricing, plan exits, and improved Star ratings.
- Optum Health turnaround: Improving execution in the Optum segment is central to the bull case.
- Valuation: A forward P/E near 17 is below UnitedHealth's historical premium, leaving room for multiple expansion if confidence returns.
- Target revisions: Several firms raised targets after the Q3 print, a sign of improving sentiment.
What Could Prevent the Target From Being Reached
- Regulatory and policy risk: An ongoing Department of Justice probe and Medicare rate uncertainty could cap the multiple.
- Medical-cost pressure: Elevated costs in Medicare Advantage and commercial plans could delay margin recovery.
- Valuation compression: Cautious analysts argue the stock already reflects much of the expected 2027–2028 rebound.
- Optum execution risk: The turnaround remains unproven and could disappoint.
- Concentration: As a diversified managed-care and health-services giant, UNH is sensitive to any single policy or regulatory shift.
Technical Levels and Market Structure
The most important resistance level is the 52-week high near $461.62; a push toward $480 would first require clearing that prior peak. Nearer term, the shares sit just below the psychologically significant $400 mark. On the downside, the 60-day moving average near $391 and the prior consolidation zone in the $370s are the first notable support levels, with deeper support in the $350 area. The long-term structure remains one of recovery from the 2025–2026 selloff rather than a fresh breakout.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms frame their targets around different assumptions for 2027 and 2028 earnings and rate cycles. Key items to watch include quarterly earnings and guidance, Medicare Advantage rate notices, Star ratings updates, any developments in the Department of Justice investigation, Optum Health margin trends, and changes to analyst targets and ratings. From what I see, this is important because it highlights where sentiment could shift next.
Using AI Daily Buy/Sell Signals for UNH
Tickeron's AI Daily Buy/Sell Signals provide a practical way to monitor UNH alongside fundamental analysis. I find them useful for spotting shifts in technical behavior that complement the earnings and regulatory updates under review.
Final Assessment
The $480 central target for UnitedHealth Group (UNH) is a calculated average of recent analyst price targets, not an official published consensus or a prediction. It implies a roughly 22% advance from the current price near $394, a substantial move that would take the stock to new 52-week highs. The case rests on raised guidance, expected Medicare Advantage and Optum margin recovery, and a below-average valuation, while the obstacles are regulatory risk, medical-cost pressure, and the argument that much of the recovery is already priced in. The wide $380-to-$531 analyst range underscores genuine disagreement, and investors should monitor earnings, rate notices, and the Department of Justice probe rather than treat any single target as a forecast.
Exploring Tickeron AI Tools
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to add real-time technical context to holdings like UNH. The platform scans thousands of stocks continuously, which helps surface opportunities and track trends without replacing core fundamental work. It has become a regular part of how I cross-check analyst views and market structure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for UNH turns negative, indicating new downward trend
UNH saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 58 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 18 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 27 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +2.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 186 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 109 of 245 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement